CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

VectorY broadens global PIONEER-ALS clinical trial cohort

Phase 1VTx-002Positive
AI Analysis

Summary

VectorY Therapeutics has expanded the study size for its global Phase I/II PIONEER-ALS clinical trial of VTx-002 for amyotrophic lateral sclerosis (ALS).

Clinical Trial Data

Phase

Phase I/II

Importance:4/10
Sentiment:
0.30
clinical trialALSPhase I/IItrial expansion
Related Companies

Read the original article

Published by Clinical Trials Arena on September 30, 2026 9:53 AM

Read Original